...This article has been updated to reflect that Dicerna is eligible for $60 million in milestones...
...in Phase III testing.Dicerna sells Oxlumo royalty rightsRoyalty Pharma plc (NASDAQ:RPRX) acquired the royalty interest of Dicerna Pharmaceuticals Inc....
...a 2020 non-exclusive IP deal between Dicerna and Alnylam related to the companies’ PH programs. Dicerna...

...AAT therapies, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and Dicerna Pharmaceuticals Inc....
...$300 million.That deal came six months after Dicerna...

...Takeda that could help it compete with Dicerna...
...exclusive rights. The deal comes six months after Dicerna Pharmaceuticals Inc....
...—its own DCR-A1AT, and Alnylam's ALN-AAT02. Dicerna...

...manufacturing facility in Ireland, which it says will be operational in 2021. RNAi therapeutics company Dicerna Pharmaceuticals Inc....
...autoimmune diseases (see “Kira: Depleting Activated Dendritic Cells” ). Robin Sawka, BioCentury Staff Alexion Pharmaceuticals Inc. WuXi Biologics Inc. Dicerna Pharmaceuticals Inc. Valneva...

...was director of the Center for Lymphoid Malignancies at Columbia University Medical Center. RNAi company Dicerna Pharmaceuticals Inc....
...of commercial development at Pfizer Inc. (NYSE:PFE) in 2009-12. Robin Sawka, BioCentury Staff TG Therapeutics Inc. FogPharma Gemini Therapeutics Inc. Dicerna Pharmaceuticals Inc. Lodo...

...and technical operations, effective May 4. Guyer was SVP of operations at BMS. RNAi company Dicerna Pharmaceuticals Inc....
...Nash will temporarily assume the role of executive chairman. Robin Sawka, BioCentury Staff Frazier Healthcare Partners BioMarin Pharmaceutical Inc. Dicerna Pharmaceuticals Inc. Zogenix...

...in Europe” ). Alnylam, Dicerna developing RNAi liver disease therapies Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Dicerna Pharmaceuticals Inc....
...the pair also granted each other non-exclusive cross-licenses to their respective primary hyperoxaluria (PH) programs. Dicerna...
...opt in to ex-U.S. commercialization of the selected candidate. The cross-licenses for Alnylam's lumasiran and Dicerna's...

...those programs.” Nodelman’s RNA interests include Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Dicerna Pharmaceuticals Inc....
...by Novartis AG (NYSE:NVS) for $9.7 billion. An updated regulatory plan has not been disclosed. Dicerna...

...oligonucleotide stabilization technology in-licensed from Osaka University-spinout Luxna Biotech Co. Ltd. Several other companies, including Dicerna Pharmaceuticals Inc....

...RNAi technology to its toolkit though a liver-focused deal with Dicerna. The partners will use Dicerna's...
...of 2.3 million shares at $21.93, a 14% premium to Dicerna's Friday close of $19.30. Dicerna...
...programs targeting cardiometabolic disorders; Dicerna can opt in to co-develop two programs during clinical development. Dicerna...